Seattle Genetics has completed the acquisition of Cascadian Therapeutics for $614m.
Based in Switzerland, Seattle Genetics is a biotechnology company, while Cascadian Therapeutics is a US-based biopharmaceutical company.
Go deeper with GlobalData
The target company is currently developing the oral tyrosine kinase inhibitor Tucatinib for the treatment of HER2 growth factor receptor overexpressed cancers.
Tucatinib is being investigated in a pivotal trial called HER2CLIMB. The drug has already demonstrated a favourable tolerability and efficacy profile in phase Ib trials.
The acquisition will strengthen Seattle Genetics’ late-stage cancer drug pipeline and establish it as a multi-product oncology company.
Gryphon Investors has acquired Matrixx Initiatives from a division of H.I.G. Capital.
Based in the US, Gryphon Investors is a private equity firm, while Matrixx Initiatives, also based in the US, is an over-the-counter (OTC) healthcare company.
India-based private equity firm ChrysCapital has acquired a minority stake in Curatio Healthcare Pvt. Ltd for Rs1.3bn ($20m).
Based in India, the target company is a manufacturer of skincare products.
The managing director of Curatio, G.K. Ramani, and Fulcrum Venture India hold 67% of the share in the company, while the remaining share is held by Sequoia Capital.
Ramani has diluted his stake in the company and Fulcrum has made a partial exit.
